Benefits of GLP-1 drugs in diabetes outweigh pancreatic harm, says MHRA

摘要

DIABETES patients should continue taking incretin-based therapies, despite reports questioning whether the pancreatic damage from these drugs has been underplayed. The Medicines and Healthcare products Regulatory Agency says the risk of pancreatitis and pre-cancerous pancreatic changes with incretin mimetics is already known, and the necessary warnings set out in the product information. Healthcare professionals should continue to prescribe these drugs and there is no need for patients to stop taking them, it says.